Home LiteratureArticle Details
PMID: 7023791 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial

Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states.

Clinical pharmacology and therapeutics ·Vol. 30 ·No. 3 ·1981-09-00 ·Pages 385-9

Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, Meisinger MA, Huber PB, Hall TL, Yeh KC

Abstract

Diflunisal is long-acting salicylate derivative. We examined the effect of single concomitant doses of three antacids on diflunisal bioavailability under fasting or fed conditions (30 min after finishing a standard meal). With the use of an open, randomized, and balanced design, one 250-mg diflunisal tablet was given to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area uiven to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area uiven to each of 12 healthy men under six conditions: fasted, no antacid; fed, no antacid; fasted, 15 ml of aluminum hydroxide gel; fed, 15 ml of aluminum hydroxide gel; fasted, 10 ml magnesium hydroxide suspension; and fed, 15 ml of an aluminum hydroxide/magnesium hydroxide mixture. Diflunisal plasma 0- to 48-hr area under the time curve (AUC), peak plasma concentrations, and 0-to 96-hr urinary excretion were determined. Food (alone) decreased peak plasma concentrations by 16% (P less than 0.05) but did not affect AUC or urinary excretion. Under fasting conditions, aluminum hydroxide reduced AUC by 26% (P less than 0.01), peak plasma concentrations by 46% (P less than 0.01), and urinary excretion by 14% (P less than 0.05). Magenisuum hydroxide suspension (in the fasting state) increased the early plasma concentrations (by 130% at 0.5 hr and 64% at 1 hr, P less than 0.05) and increased AUC by 10% (P less than 0.05) but had no effect on urinary excretion. In the fed state neither aluminum hydroxide nor the aluminum hydroxide/magnesium hydroxide mixture had any detectable effect.

MeSH Terms
Adult Aluminum Hydroxide/metabolism Antacids/pharmacology Biological Availability Clinical Trials as Topic Diflunisal/blood,metabolism,urine Fasting Food Gels Humans Magnesium Hydroxide/metabolism Male Salicylates/metabolism Suspensions Time Factors
Chemicals
Antacids Gels Salicylates Suspensions Aluminum Hydroxide Diflunisal Magnesium Hydroxide
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Tobert J A
DeSchepper P
Tjandramaga T B
Mullie A
Buntinx A P
Meisinger M A
Huber P B
Hall T L
Yeh K C
Article Info
Journal
Clinical pharmacology and therapeutics
Abbr.
Clin Pharmacol Ther
ISSN
0009-9236
Published
1981-09-00
Pages
385-9
Language
English
Region
United States
NLM ID
0372741
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com